HR-Related Coronavirus Q&A: Our Answers to Your Questions
Client Alert | 1 min read | 04.21.20
We have drafted an ‘HR-Related Coronavirus Q&A’ in response to recent developments, and we thought that it might be of interest to you. You will find this Q&A here. In it, we take a look at our clients’ most commonly asked questions regarding the impact of the virus.
The questions and answers in this Q&A are of course of a general nature and should not be considered to be comprehensive legal advice on specific questions and/or cases. Do not hesitate to contact our team if you have any specific questions and/or would like any advice with regard to a concrete situation.
You will also find ‘Coronavirus Workplace Guidelines’ for US employers, which include useful tips and recommendations of a general reach as well (EU-based employers may disregard the US-specific guidelines).
Our team will continue to closely monitor developments and keep you posted.
Contacts
Insights
Client Alert | 8 min read | 04.17.26
CMS Finalizes CY 2027 Medicare Advantage and Part D Rule: Key Implications for Plan Sponsors
On April 6, 2026, the Centers for Medicare & Medicaid Services (CMS) published its final rule governing the Medicare Advantage (Part C) and Prescription Drug Benefit (Part D) programs for Contract Year (CY) 2027. The final rule is effective June 1, 2026, with most provisions applicable to coverage beginning January 1, 2027, and marketing and communications changes taking effect October 1, 2026. Beyond payment, the rule pursues a broad deregulatory agenda aligned with Executive Order 14192, reversing marketing and enrollment safeguards introduced in 2023 and easing documentation and reporting obligations, while introducing new program integrity requirements.
Client Alert | 1 min read | 04.17.26
Client Alert | 3 min read | 04.17.26
Client Alert | 2 min read | 04.16.26
